155 related articles for article (PubMed ID: 38411373)
1. Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations.
Liu XL; Run-Hua Z; Pan JX; Li ZJ; Yu L; Li YL
Pigment Cell Melanoma Res; 2024 May; 37(3):411-425. PubMed ID: 38411373
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives.
Croce M; Ferrini S; Pfeffer U; Gangemi R
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31216772
[TBL] [Abstract][Full Text] [Related]
3. Genomic Profiling of Metastatic Uveal Melanoma Shows Frequent Coexisting BAP1 or SF3B1 and GNAQ/GNA11 Mutations and Correlation With Prognosis.
Isaacson AL; Sompallae RR; Guseva NV; Bellizzi AM; Bossler AD; Ma D
Am J Clin Pathol; 2022 Aug; 158(2):177-186. PubMed ID: 35212356
[TBL] [Abstract][Full Text] [Related]
4. How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma.
Marseglia M; Amaro A; Solari N; Gangemi R; Croce E; Tanda ET; Spagnolo F; Filaci G; Pfeffer U; Croce M
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922591
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
6. Genetic and clinico-pathologic analysis of metastatic uveal melanoma.
Griewank KG; van de Nes J; Schilling B; Moll I; Sucker A; Kakavand H; Haydu LE; Asher M; Zimmer L; Hillen U; Thompson JF; Scolyer RA; Schadendorf D; Murali R
Mod Pathol; 2014 Feb; 27(2):175-83. PubMed ID: 23887304
[TBL] [Abstract][Full Text] [Related]
7. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.
Decatur CL; Ong E; Garg N; Anbunathan H; Bowcock AM; Field MG; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):728-33. PubMed ID: 27123562
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.
Ewens KG; Kanetsky PA; Richards-Yutz J; Purrazzella J; Shields CL; Ganguly T; Ganguly A
Invest Ophthalmol Vis Sci; 2014 Jun; 55(8):5160-7. PubMed ID: 24970262
[TBL] [Abstract][Full Text] [Related]
9. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG
Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597
[TBL] [Abstract][Full Text] [Related]
10. Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.
Hou C; Xiao L; Ren X; Tang F; Guo B; Zeng W; Liang C; Yan N
Ophthalmic Res; 2020; 63(3):358-368. PubMed ID: 31614358
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma.
Patrone S; Maric I; Rutigliani M; Lanza F; Puntoni M; Banelli B; Rancati S; Angelini G; Amaro A; Ligorio P; Defferrari C; Castagnetta M; Bandelloni R; Mosci C; DeCensi A; Romani M; Pfeffer U; Viaggi S; Coviello DA
Genes Chromosomes Cancer; 2018 Aug; 57(8):387-400. PubMed ID: 29689622
[TBL] [Abstract][Full Text] [Related]
12. PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma.
Park JJ; Hamad SA; Stewart A; Carlino MS; Lim SY; Rizos H
Oncogenesis; 2024 Feb; 13(1):9. PubMed ID: 38418838
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma.
Akin-Bali DF
Ophthalmic Genet; 2021 Dec; 42(6):732-743. PubMed ID: 34353217
[TBL] [Abstract][Full Text] [Related]
14. Emerging Therapeutic Opportunities Based on Current Knowledge of Uveal Melanoma Biology.
Vivet-Noguer R; Tarin M; Roman-Roman S; Alsafadi S
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31330784
[TBL] [Abstract][Full Text] [Related]
15. New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma.
Wei AZ; Maniar AB; Carvajal RD
Cancer Gene Ther; 2022 Dec; 29(12):1819-1826. PubMed ID: 35236928
[TBL] [Abstract][Full Text] [Related]
16. Combined PKC and MEK inhibition for treating metastatic uveal melanoma.
Sagoo MS; Harbour JW; Stebbing J; Bowcock AM
Oncogene; 2014 Sep; 33(39):4722-3. PubMed ID: 24413085
[TBL] [Abstract][Full Text] [Related]
17. Uveal melanoma: epidemiology, etiology, and treatment of primary disease.
Krantz BA; Dave N; Komatsubara KM; Marr BP; Carvajal RD
Clin Ophthalmol; 2017; 11():279-289. PubMed ID: 28203054
[TBL] [Abstract][Full Text] [Related]
18. Genetics and RNA Regulation of Uveal Melanoma.
Barbagallo C; Stella M; Broggi G; Russo A; Caltabiano R; Ragusa M
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765733
[TBL] [Abstract][Full Text] [Related]
19. Chromosomal rearrangements in uveal melanoma: Chromothripsis.
van Poppelen NM; Yavuzyigitoglu S; Smit KN; Vaarwater J; Eussen B; Brands T; Paridaens D; Kiliç E; de Klein A
Genes Chromosomes Cancer; 2018 Sep; 57(9):452-458. PubMed ID: 29726589
[TBL] [Abstract][Full Text] [Related]
20. Uveal melanoma: progress in molecular biology and therapeutics.
Li Y; Shi J; Yang J; Ge S; Zhang J; Jia R; Fan X
Ther Adv Med Oncol; 2020; 12():1758835920965852. PubMed ID: 33149769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
